Clinical development failure
The company’s value depends on successful trial outcomes for azenosertib and other candidates.
- Scope
- Azenosertib and pipeline assets
- Materiality
- high
Zentalis Pharmaceuticals, Inc.
Zentalis Pharmaceuticals is a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing small-molecule cancer therapies. Its pipeline is centered on azenosertib and other compounds licensed from third parties, with development activities organized through its wholly owned subsidiaries.
−100,0 %
6.93
6.93
| % | |
|---|---|
| Clinical-stage oncology programs | 90% Drug candidates in preclinical and clinical development for cancer indications. |
| License revenue and collaborations | 10% Upfront, milestone, or other revenue from licensing intellectual property to partners. |
Zentalis does not sell approved medicines directly to patients or hospitals; its counterparties are primarily...
- Licensing and collaboration partnersprimary
Pharmaceutical or biotech counterparties that fund, co-develop, or commercialize pipeline assets.
- Intellectual property licensorsprimary
Owners of licensed technology and patents, including parties behind the Recurium agreement.
- Future oncology treatment providersemerging
Oncologists, hospitals, and cancer centers that would use approved products if development succeeds.
- Clinical trial ecosystemprimary
Investigators, CROs, and trial sites that support patient enrollment and study execution.
Zentalis is headquartered in the United States and operates as a U.S.-based development company, while its licensing...
- •Headquartered in the United States
- •Worldwide license rights for key pipeline intellectual property
- •Clinical development footprint follows trial-site geography
- •No disclosed country revenue mix from product sales
- •Global regulatory exposure through ex-U.S. approvals and trials
Zentalis’ strategy is to advance azenosertib and other licensed oncology assets through clinical development and, if...
01
Advance azenosertib clinical developmentshort-term
The lead program is the core value driver and the main path to regulatory approval.
02
Secure partnerships and strategic transactionsmedium-term
Collaborations can provide capital, development support, and commercialization reach.
03
Build commercialization readinessmedium-term
A successful asset will require manufacturing, regulatory, and commercial infrastructure.
Zentalis faces the typical risks of a clinical-stage biopharmaceutical company: no approved products, heavy dependence...
Financing risk
The company has no product-sales revenue and must fund R&D and trials through external capital.
- Scope
- Operating runway and development pace
- Materiality
- high
Regulatory approval risk
Drug candidates must satisfy FDA and other regulators before commercialization.
- Scope
- Late-stage oncology programs
- Materiality
- high
Competition from larger oncology developers
Well-funded peers may advance similar mechanisms or approved therapies faster.
- Scope
- Targeted cancer indications
- Materiality
- medium
License and IP dependency
Key assets are based on third-party licensed intellectual property with contractual obligations.
- Scope
- Recurium agreement and related rights
- Materiality
- medium
License revenue recognition
Can create quarter-to-quarter volatility in reported revenue
Research and development expense
Drives operating loss and reflects pipeline progress
Fair value of equity securities
Can materially move non-operating results
Net operating loss carryforwards
Affects deferred tax asset recognition and tax expense
Restructuring accruals
Affects operating expenses and comparability across periods
Zenas BioPharma, Inc.
ZBIO · Pharmaceutical Preparations
Zenas BioPharma is a U.S.-based clinical-stage biopharmaceutical company focused on immunology and inflammation therapies for autoimmune diseases.
LeonaBio, Inc.
LONA · Biological Products, (No Diagnostic Substances)
Nuvalent, Inc.
NUVL · Pharmaceutical Preparations
Relay Therapeutics, Inc.
RLAY · Biological Products, (No Diagnostic Substances)
GENELUX Corp
GNLX · Pharmaceutical Preparations
GENELUX Corp is a U.S.-based clinical-stage biopharmaceutical company focused on developing oncolytic vaccinia virus immunotherapies, led by its Olvi-Vec program.
Oncotelic Therapeutics, Inc.
OTLC · Pharmaceutical Preparations
: 29/04/2026